US pharmacy giant buys rival for $29.1 billion
Pharmacy benefits manager Express Scripts said Thursday it had reached a deal to buy its competitor Medco Health Systems for $29.1 billion, ahead of looming changes in the US healthcare system.
Pharmacy benefits managers, or PBMs, work with employers and health insurers to obtain cheaper prescription drugs by pushing pharmaceutical companies to give discounts on their often-pricey medicines.
The merger, if approved by regulators, would be a big step to consolidating the PBM industry at a time when President Barack Obama's healthcare reform initiative is poised to provide insurance to millions of Americans.
"The cost and quality of healthcare is a great concern to all Americans; this is the right deal at the right time for the right reasons," Express Scripts chief executive George Paz said in a statement.
Shares of Medco surged 14 percent on the New York Stock Exhange by midday, while Express Scripts stock was up 5.1 percent.
Under the terms of the deal, Medco shareholders would receive $71.36 in cash and Express Scripts stock for each of their shares, a premium of 28 percent to the closing price of Medco shares on Wednesday, the statement said.
The merger, which was unanimously approved by the boards of both companies, would leave Express Scripts shareholders with ownership of 59 percent of the combined firm.
If approved by shareholders and regulators, including antitrust authorities, the deal is expected to close in the first half of 2012.
Founded in 1986 and based in St. Louis, Missouri, Express Scripts reported profits of $334 million in the second quarter of 2011 on revenues of $11.36 billion.
Medco, based in Franklin Lakes, New Jersey, had profits of $342 million on revenues of $17 billion in the same quarter.
(c) 2011 AFP
-
Medco plans to compare Plavix, Effient in study
Oct 20, 2009 |
not rated yet |
0
-
Verizon to buy Terremark for $1.4 billion
Jan 28, 2011 |
not rated yet |
0
-
Churchill Downs buying YouBet.com
Nov 12, 2009 |
not rated yet |
0
-
NetApp to buy Data Domain in $1.5 billion deal
May 21, 2009 |
not rated yet |
0
-
US prescription drug use fell in 2008, study says
May 13, 2009 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
Why is zone 1 in liver more prone to ischemic injury?
May 23, 2013
-
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013
-
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
- More from Physics Forums - Medical Sciences
More news stories
Merck ends development of Parkinson's disease drug
(AP)—Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.
Medications
May 23, 2013 |
1 / 5 (1) |
0
J&J expects 10-plus new drug applications by 2017
(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...
Medications
May 23, 2013 |
5 / 5 (1) |
0
Experts favor US approval of Merck sleeping pill (Update)
An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.
Medications
May 22, 2013 |
not rated yet |
0
Glaxo, US partnering to develop new antibiotics
GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.
Medications
May 22, 2013 |
not rated yet |
0
Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine
The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published ...
Medications
May 22, 2013 |
not rated yet |
0
Researchers identify first drug targets in childhood genetic tumor disorder
Two mutations central to the development of infantile myofibromatosis (IM)—a disorder characterized by multiple tumors involving the skin, bone, and soft tissue—may provide new therapeutic targets, according to researchers ...
Engineered cytomegalovirus protects monkeys from HIV equivalent
(Medical Xpress)—A new study by researchers in the US has shown that an ancient virus can be modified to help in the fight against the simian immunodeficiency virus SIV, which is the equivalent in monkeys ...
Hormone levels may provide key to understanding psychological disorders in women
Women at a particular stage in their monthly menstrual cycle may be more vulnerable to some of the psychological side-effects associated with stressful experiences, according to a study from UCL.
Going live: Immune cell activation in multiple sclerosis
Biological processes are generally based on events at the molecular and cellular level. To understand what happens in the course of infections, diseases or normal bodily functions, scientists would need to ...
Driving and hands-free talking lead to spike in errors, study shows
Talking on a hands-free device while behind the wheel can lead to a sharp increase in errors that could imperil other drivers on the road, according to new research from the University of Alberta.
Pollen count apps for smartphones are nothing to sneeze at
Kate O'Reilly's spring allergy survival kit includes the usual stuff - nasal sprays, allergy pills and a box of tissues. This season, she's added a new weapon to her line of defense: an app on her smartphone.